If you have been comparing Mounjaro and Wegovy, it is easy to feel more confused the more you read. Both are weekly injections. Both can help with weight loss. Both work on gut hormone pathways involved in appetite and fullness. But they are not the same medication, and they do not suit every patient in the same way.
Mounjaro contains tirzepatide, which acts on both GLP-1 and GIP receptors. Wegovy contains semaglutide, which acts on GLP-1 receptors. In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss than semaglutide at 72 weeks — around 20.2% of body weight compared with around 13.7%. That is a meaningful difference, but it does not automatically make Mounjaro the right choice for everyone.
The right decision depends on your medical history, other medications, side-effect tolerance, cardiovascular risk, previous response to treatment, goals and the level of support you need around the medication. This guide explains how Mounjaro and Wegovy differ, where each may fit better, and why the decision should be made through proper clinical review rather than by choosing whichever looks strongest on paper.
The Short Answer
Mounjaro and Wegovy both help you feel full sooner and eat less. Mounjaro tends to produce more weight loss on average, but it can also cause more gastrointestinal side effects for some people. Wegovy has a longer real-world track record and, for people with existing heart disease, has a specific NICE recommendation behind it. Neither is automatically “better.” The right one depends on your health history, your goals, and how your body responds, which is why this decision should be made with a GP or clinician following assessment and discussion, not guessed at.
| Key Point | Mounjaro | Wegovy |
| Active ingredient | Tirzepatide | Semaglutide |
| How it works | Activates GLP-1 and GIP receptors | Activates GLP-1 receptor only |
| Average weight loss (72 weeks, head-to-head trial) | Around 20.2% of body weight | Around 13.7% of body weight |
| Common side effects | Nausea, diarrhoea, reduced appetite | Nausea, constipation, reduced appetite |
| Best suited for | A stronger average response, no major GI sensitivity | May be considered where cardiovascular outcomes evidence is especially relevant, or where semaglutide is better tolerated |
| Available privately from | Medica Universal | Medica Universal |
Want to know which one fits your health history? Medica Universal’s clinical team reviews your case properly before recommending either medication.
How Each One Works, In Simple Terms
Both medications copy hormones your gut releases naturally after eating. These hormones tell your brain you’re full and slow down how fast your stomach empties, which is why you feel satisfied on less food.
The difference is in how many of these hormone pathways they target.
Wegovy contains semaglutide. It copies one hormone: GLP-1 (glucagon-like peptide-1), a hormone that increases insulin release and reduces appetite.
Mounjaro contains tirzepatide. It copies two hormones: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), a second gut hormone involved in insulin release and fat metabolism. Activating both pathways appears to produce a stronger overall effect on appetite and blood sugar control.
Neither medication “burns fat” directly. They work mainly by reducing appetite and helping people eat less, which puts the body into a calorie deficit. That’s exactly why nutrition support matters alongside them. When appetite drops sharply, it becomes easy to under-eat protein, skip fibre, or simply eat less of everything rather than eating well. Structured support helps patients keep protein intake up, stay hydrated, maintain some resistance training to protect muscle, and avoid the nutritional gaps that come from eating less on autopilot. The aim isn’t just weight loss. It’s losing fat while protecting muscle, which is a different, better outcome.
Our wider guide to GLP-1 weight loss injections covers this in more depth and is worth reading if you’re still deciding whether this type of treatment is right for you at all.
Differences in Effectiveness
This is where most patients want a straight answer, so here it is.
In the SURMOUNT-5 trial, the first direct head-to-head comparison of the two drugs, researchers followed 751 adults with obesity for 72 weeks. Both groups took the highest dose they could tolerate. Tirzepatide (Mounjaro) produced greater average weight loss than semaglutide (Wegovy) at 72 weeks: around 20.2% of body weight compared with around 13.7%. Mounjaro also produced a bigger reduction in waist circumference, which matters because it reflects a change in body shape, not just a number on the scale.
That difference is clinically meaningful, but it’s still an average across a trial population. It doesn’t mean every patient will lose more weight on Mounjaro, or that Wegovy is the wrong choice. Not every patient is a high responder to either medication. Some patients lose a large amount of weight, some lose a moderate amount, and a smaller group have a limited response despite taking the medication correctly. This is one of the main reasons regular review matters: a clinician can work out whether a limited response is down to dose, nutrition, adherence, side effects, unrealistic expectations, or whether a different strategy is needed altogether.
Side Effects Comparison
Both medications commonly cause gastrointestinal side effects, because they work on overlapping pathways. This is well documented and expected. It doesn’t mean either medication is usually intolerable.
Wegovy: the product information lists gastrointestinal disorders, including nausea, diarrhoea, constipation and vomiting, as the most frequently reported reactions. In pooled data from the STEP 1 to 3 trials, nausea was reported in around 43.9% of patients and constipation in around 24.2%, compared with 16.1% and 11.1% on placebo. Despite this, gastrointestinal side effects led to permanent discontinuation of the medication in only 4.3% of patients, suggesting that although gastrointestinal symptoms are common, most patients do not stop treatment because of them.
Mounjaro: nausea, diarrhoea, vomiting, constipation and abdominal pain are recognised common gastrointestinal reactions. In the original SURMOUNT-1 trial, side effects led to discontinuation in 4.3%, 7.1% and 6.2% of patients across the 5mg, 10mg and 15mg doses, compared with 2.6% on placebo, again suggesting that although side effects are common, most patients do not stop treatment because of them.
What this actually means for you:
- Gastrointestinal symptoms are common, especially during dose escalation
- Most patients do not stop treatment because of them
- Symptoms are usually mild to moderate and settle as the body adjusts
- Slow titration, clear side-effect guidance and regular review are what keep most patients on track
If you’re weighing up side effects against results, Medica Universal’s clinicians talk you through both before you commit to either medication.
Who Each Is Better Suited For
Mounjaro may suit you better if:
- You want the strongest average weight loss response
- You don’t have a history of significant digestive sensitivity
- You’ve plateaued on semaglutide previously
Wegovy may suit you better if:
- You have established cardiovascular disease, since NICE now specifically recommends semaglutide alongside diet and physical activity to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and a BMI of 27 or above. This is a genuine clinical consideration, not a reason to assume Wegovy is always the better choice for anyone with a heart history
- You’re more prone to constipation-type side effects than diarrhoea
- You prefer a gentler onset of appetite suppression
Neither list is exhaustive. Your clinician will also factor in your weight, any existing conditions such as type 2 diabetes, your medication history, cardiovascular risk, side-effect tolerance and your personal goals before recommending one over the other.
Why This Choice Should Be Personalised
A simple comparison chart can tell you which medication produced greater average weight loss in a trial. It can’t tell you which option best fits your medical history, tolerance, goals and long-term plan. That gap is exactly what a proper consultation is for.
At Medica Universal, everything starts with a detailed assessment, reviewed by a clinician, not a basic eligibility form working alone. From there, patients are matched to the right level of support for where they are: GP-led active treatment for those starting or adjusting medication, nurse-led support for suitable, lower-risk patients, and nutrition and lifestyle guidance built in depending on the package. Maintenance planning starts from day one, not as an afterthought once the weight is off.
A proper clinical review looks at your full picture: blood pressure, blood glucose and kidney function where relevant, other medications, previous response, side effect tolerance and your realistic day-to-day routine. That’s the insider detail most comparison articles miss. The “better” drug on a trial chart isn’t always the better drug for the person reading this.
Pre-Action Checklist
Before starting either Mounjaro or Wegovy, make sure you can answer yes to the following:
- [ ] I have completed a detailed assessment that is clinically reviewed, rather than relying on a basic eligibility form alone
- [ ] My case has reviewed by a clinician, with GP input where my history or medications make that appropriate
- [ ] I understand the realistic timeline for results, not an inflated one
- [ ] I have a follow-up plan for dose adjustments and side effect monitoring
- [ ] I have a plan for what happens after I reach my goal weight
Common Mistakes to Avoid
- Choosing based on price alone. The right choice depends on your health profile, not just the monthly cost.
- Assuming higher average weight loss means it’s right for you. Trial averages don’t account for your individual tolerance or health history.
- Increasing the dose too quickly. This is the most common cause of severe nausea and early treatment dropout.
- Assuming blood tests are always unnecessary. Blood tests are not required for every patient, but they can be useful where medical history, symptoms or risk factors suggest they may change the recommendation.
- Stopping suddenly without a plan. Weight regain is common when medication stops abruptly without ongoing support.
What to Do Next
- Complete a detailed online assessment. This should cover your medical history review, current medications, weight history and goals, not just a basic eligibilty form.
- Have your assessment clinically reviewed. Straightforward cases may be suitable for nurse-led support, while more complex histories may need GP input.
- Arrange blood tests if clinically recommended. These can be useful where your history, symptoms or risk factors suggest they may change the recommendation.
- Discuss both medications honestly. Ask which option fits your specific health profile and why, not just which one is trending.
- Agree a starting dose, titration plan and follow-up schedule before you start. This is where side effects, dose changes and accountability are managed.
Ready to find out which medication actually fits your health profile? Get a personalised plan from Medica Universal’s clinician-led team.
Medica Universal is not built around automatic prescribing. Our process starts with a detailed assessment, but the important part is how that information is reviewed and used. Patients are matched to the right level of support, whether that’s GP-led active treatment, nurse-led support, nutrition guidance, dose review or maintenance planning. If you want to understand how prescribing decisions are actually made here, our services page and our guide to weight loss injections cover this in more detail.
Frequently Asked Questions
Can I switch from Wegovy to Mounjaro, or the other way round, if it’s not working for me?
Yes, switching is possible, but it needs clinical supervision. Your clinician will review your current dose, side effects, response and timing before advising how to change treatment. Switching without guidance can increase the risk of side effects, poor tolerance or an ineffective transition, so book a review before changing anything yourself.
Do I need to be significantly overweight to qualify for either medication?
Eligibility is based on your body mass index (BMI), a measure of weight relative to height, alongside any weight-related health conditions you have, such as high blood pressure. A private GP assessment looks at your full picture rather than applying a single BMI cut-off, so it’s worth discussing your specific case directly.
How long will I likely need to stay on Mounjaro or Wegovy?
There’s no fixed timeline, and anyone promising one is overpromising. Most patients stay on treatment for months, sometimes longer, while working towards a target weight, then move to a maintenance phase. Your GP will review progress regularly and adjust the plan rather than setting an arbitrary end date upfront.
Get a Personalised Plan
Medica Universal offers two routes for patients comparing weight loss injections.
Mounjaro or Wegovy Consultation — A detailed clinical review of your medical history, medication, goals and blood tests where relevant, so you start on the medication and pathway that suits you.
Ongoing Prescribing and Follow-Up — Structured titration, regular check-ins, side-effect support and maintenance planning to help you stay on track beyond the first prescription.
To book a consultation or ask a question about either medication, Contact Medica Universal today. We will review your situation and help you understand which option is most appropriate for you.